Author

Marc E. Rothenberg

DYSPHAGIA DAYS AS A CLINICAL MARKER OF EOE TREATMENT RESPONSE
DYSPHAGIA DAYS AS A CLINICAL MARKER OF EOE TREATMENT RESPONSE

Marc E. Rothenberg  et al.

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Marc E. Rothenberg  et al.

DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

Marc E. Rothenberg  et al.

DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS
DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS

Marc E. Rothenberg  et al.

HIGH DISCOVERY RATE OF EOSINOPHILIC GASTRITIS AND/OR DUODENITIS AMONG PATIENTS WITH CHRONIC FUNCTIONAL GASTROINTESTINAL SYMPTOMS
HIGH DISCOVERY RATE OF EOSINOPHILIC GASTRITIS AND/OR DUODENITIS AMONG PATIENTS WITH CHRONIC FUNCTIONAL GASTROINTESTINAL SYMPTOMS

Marc E. Rothenberg  et al.

A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE
A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE

Marc E. Rothenberg  et al.

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS
SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS

Marc E. Rothenberg  et al.

Item 1 - 7 / 7
1